Zhao J, Liang CQ, Li W, Yao DK. Efficacy of addition of statins to interferon α and ribavirin for hepatitis C: A meta-analysis.
Shijie Huaren Xiaohua Zazhi 2017;
25:484-490. [DOI:
10.11569/wcjd.v25.i6.484]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM
To systematically evaluate the therapeutic efficacy of statins as add-on to interferon α (IFNα) plus ribavirin (RBV) therapy for hepatitis C.
METHODS
A thorough search was done in PubMed, Web of Science, EMBASE, Cochrane Library, CNKI, Wanfang Data, SinoMed and VIP to collect articles on statins as add-on to IFNα plus RBV therapy for hepatitis C. Quality of each study was assessed, and meta-analysis of sustained virological response (SVR), rapid virological response (RVR) and early virological response (EVR) was performed with RevMan5.3 software.
RESULTS
Seven randomized controlled trials were included with 202 patients in the add-on therapy group and 198 patients in the control group. Meta-analysis showed that triple therapy with IFNα, RBV and statin was superior to therapy with IFNα and RBV in achieving SVR and RVR (OR = 2.18, 95%CI: 1.42-3.34, P = 0.0004; OR = 2.37, 95%CI: 1.11-5.09, P = 0.03), while the difference in EVR was not significant (OR = 1.42, 95%CI: 0.86-2.36, P = 0.17). For hepatitis C virus genotype 1, the increase in the SVR rate remained significant (OR = 2.41, 95%CI: 1.33-4.36, P = 0.004).
CONCLUSION
The addition of statins to IFNα and RBV can improve sustained virological response and increase the cure rate in hepatitis C.
Collapse